Principles of transdermal nitroglycerin administration

European Heart Journal
H M Wolff, R Bonn

Abstract

The currently marketed delivery systems for transdermal nitroglycerin (GTN) develop fairly constant GTN plasma concentrations throughout the 24-h application period. This may be associated with tolerance, particularly when higher doses are employed. Because of this problem, a new GTN transdermal delivery system (TDS) has been developed which provides a time-dependent, non-constant drug delivery rate. This system was engineered to provide high GTN plasma concentrations during the first 12h of application which should prevent exercise-induced angina and low nitroglycerin levels during the second 12-h period to prevent tolerance. This GTN TDS with a phasic release profile is described and the in vitro and in vivo release rates and resulting plasma concentrations are contrasted with those of conventional GTN transdermal patches.

Citations

Oct 1, 1994·Cardiovascular Drugs and Therapy·M G Bogaert
Jan 1, 1990·European Journal of Clinical Pharmacology·U E Jonsson
Jan 1, 1992·European Journal of Clinical Pharmacology·T O KlemsdalJ E Bredesen
Jun 1, 1995·British Journal of Clinical Pharmacology·T O KlemsdalK Zahlsen

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antianginal Drugs: Mechanisms of Action

Antianginal drugs, including nitrates, beta-blockers, and calcium channel blockers, are used in the treatment of angina pectoris. Here is the latest research on their use and their mechanism of action.

Cardiology Journals

Discover the latest cardiology research in this collection of the top cardiology journals.